ADAR1 Capital Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

ADAR1 Capital Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$45.7M	Buy	1,222,080 +82,749	+7%	+$3.08M	2.09%	8
2026 Q1	$41.4M	Buy	1,139,331 +829,963	+268%	+$37.1M	2.44%	8
2025 Q4	$14.4M	Buy	309,368 +61,000	+25%	+$2.72M	1.06%	20
2025 Q3	$10.3M	Buy	248,368 +195,243	+368%	+$6.24M	0.97%	23
2025 Q2	$1.53M	Hold	53,125	–	–	0.23%	66
2025 Q1	$1.78M	Hold	53,125	–	–	0.33%	62
2024 Q4	$2.72M	Sell	53,125 -35,300	-40%	-$1.97M	0.54%	40
2024 Q3	$4.52M	Buy	88,425 +13,575	+18%	+$700K	0.73%	28
2024 Q2	$3.35M	Buy	+74,850	New	+$3.46M	0.63%	27

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Jupiter Topco New York $245B AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ADAR1 Capital Management's CRNX Position: Q2 2026 in Review

ADAR1 Capital Management increased its Crinetics Pharmaceuticals (CRNX) stake by 7.3% in Q2 2026, buying an estimated $3.08M and bringing the position to 1,222,080 shares worth $45.7M. The position accounts for 2.09% of the portfolio, ranked #8.

ADAR1 Capital Management first reported a position in CRNX in Q2 2024 and has held it in 9 quarters since. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

ADAR1 Capital Management held 1,222,080 shares of Crinetics Pharmaceuticals worth $45.7M as of Q2 2026.
ADAR1 Capital Management bought 82,749 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $3.08M.
Crinetics Pharmaceuticals made up 2.09% of ADAR1 Capital Management's portfolio in Q2 2026, its #8 holding.
ADAR1 Capital Management first reported a position in Crinetics Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.